Latest News

The latest in our partnerships, collaborations, company updates, and milestones.

May 15, 2024

Inimmune Announces Successful Phase 1 Clinical Results For Disease Modifying Allergy Treatment, INI-2004
May 15, 2024

Inimmune Announces Successful Phase 1 Clinical Results For Disease Modifying Allergy Treatment, INI-2004

Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis

Read More

Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout

Read More

Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients

Read More

Inimmune participates in the development of an innovative intranasal influenza vaccine

Read More

Inimmune To Present On Their Next Generation Adjuvants At World Vaccine Congress in Amsterdam

Read More
Medinvest Oncology Investor Conference
Inimmune to Present at the Medinvest Oncology Conference on INI-4001
Read
World Vaccine Congress
Inimmune to present an Update on Clinical Stage Vaccine Adjuvant and Immunotherapy Programs at the World Vaccine Congress in Washington DC on April 1st
Read
Medinvest Oncology Investor Conference
Inimmune to Present on Our Novel Cancer Immunotherapy INI-4001
Read
World Vaccine Congress (West Coast)
Inimmune to Provide an Update on Our Vaccine and Adjuvant Programs
Read